Court Rejects Theory Of Derivation Based On FDA Requirement

by Foley & Lardner LLP

The Federal Circuit decision in Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC may be more interesting for what Mylan argued than for what the Federal Circuit decided. However, it could be an important decision for pharmaceutical companies who need to innovate in order to satisfy FDA requirements.

The Patent At Issue

The patent at issue was Cumberland’s U.S. 8,399,445, directed to method of treating acetaminophen overdose using a formulation of acetylcysteine that is “free of chelating agents”:

1. A method of treating acetaminophen overdose, comprising:
using a stable aqueous pharmaceutical composition comprising 200 mg/ml acetylcysteine or pharmaceutically acceptable salts thereof, wherein the composition is free of chelating agents, wherein said composition is in a suitable form for intravenous injection, wherein the pH of the composition is from 6 to 7.5, and wherein said composition is sealed in an airtight container comprising a fill volume of said composition and a headspace volume occupied by a pharmaceutically inert gas;
diluting the composition in an aqueous solution; and
administering the diluted composition to a patient in need thereof.

According to the Federal Circuit opinion, the use of acetylcysteine as an antidote for acetaminophen overdoses was known in the prior art, but it also was known that acetylcysteine had stability problems. In particular, “heavy metal ions, whether inherent in the formula or found as contaminants, catalyze the oxidation of acetylcysteine in solution, causing it to degrade.” While the prior addressed this problem by formulating acetylcysteine with a chelator (EDTA), the inventor of the ‘445 patent discovered an alternative way to prepare a stable formulation without a chelating agent.

The FDA’s Role In The Invention

The Federal Circuit opinion summarizes the genesis of the invention as follows:

In 2002, several years before the 2005 filing date of the ‘445 patent, Cumberland was seeking FDA approval for its Acetadote® product, which was an “EDTA-containing formulation” of acetylcysteine. As part of its usual review process, the FDA asked Cumberland to justify the presence of EDTA in the formulation “since a non-trivial amount” is present. While Cumberland continued to pursue FDA approval of Acetadote®, the inventor (who was involved in the FDA review process) endeavored to determine whether a stable formulation could be prepared without EDTA. The FDA encouraged this research, and approved Acetadote® after Cumberland “committ[ed] to evaluate the potential benefit of [EDTA] on the stability of the drug product” and study “a formulation with a lower concentration and no concentration.”

Pursuant to that commitment, the inventor designed a protocol that included a formulation within the scope of the claims of the ‘445 patent, the FDA approved the experimental design without change, and the results were “encouraging.” The patent application was filed in August 2005, and the FDA approved an EDTA-free formulation of Acetadote® in January 2011.

Did Cumberland Derive The Invention From The FDA?

The appeal at issue arose from ANDA litigation filed in response to Mylan’s Abbreviated New Drug Application seeking approval to market a generic version of Cumberland’s EDTA-free formulation of Acetadote®.

Mylan’s argued that the patent is invalid because: (1) the invention was derived from someone at the FDA who suggested to remove EDTA from the prior-art formulation and (2) the EDTA-free formulation would have been obvious. The district court disagreed on both issues, finding that “Mylan had not proved that anyone at the FDA conceived of the invention before Cumberland’s inventor did,” and that “there was no reasonable expectation that a formulation without any chelating agents would be successful, given the prevailing skilled-artisan view that chelating agents were necessary.”

Invalidity due to “derivation” is based on 35 U.S.C. § 102(f), which holds that a person is entitled to a patent “unless … he did not himself invent the subject matter sought to be patented.” To establish invalidity due to derivation, the challenger must establish “prior conception of the claimed subject matter [by a third party] and communication of the conception” to the inventor.

The Federal Circuit Decision

The Federal Circuit decision was authored by Judge Taranto and joined by Judges Moore and Reyna.

The Federal Circuit focused on the legal question embodied in the derivation claim–“whether there was a prior conception” of the invention–and noted that “conception must encompass all limitations of the claimed invention” in the context of a “specific, settled idea.” Applying this legal standard to the case at hand, the court summarized Mylan’s burden as follows:

Mylan had to show, by clear and convincing evidence, a conception by someone at the FDA that included “the specific idea to remove EDTA … and not add another chelating agent,” and a communication of that conception to Mr. Pavliv.

The Federal Circuit agreed with the district court that there was a “paucity of direct evidence” supporting such a scenario. The court noted that the FDA’s requirement that Cumberland justify the presence of EDTA did not amount to “a suggest to remove it, let alone to remove it and not replace it with another chelating agent.” The court rejected Mylan’s argument that derivation could be based on FDA’s “request for data to support the inclusion of EDTA,” since that allegedly “required Cumberland to undertake research that would have inevitably led it to the invention.”

The kind of general research suggestion at issue here, whatever its role in an obviousness analysis, does not establish the conception required for derivation.

Turning to the obviousness analysis, the Federal Circuit agreed with the district court Mylan had failed to show that a person of ordinary skill in the art would have had a reasonable expectation of success in preparing a stable formulation of acetylcysteine without a chelating agent, as recited in the claims. The Federal Circuit affirmed this finding despite Mylan’s citation of prior art that described an acetylcysteine formulation that did not include a chelating agent, since that reference did not provide stability data on that formulation. Thus, the district court’s judgment rejecting the invalidity claims was affirmed.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley & Lardner LLP | Attorney Advertising

Written by:

Foley & Lardner LLP

Foley & Lardner LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.